#USA #New York #Healthcare Conference #Halia Therapeutics #Jefferies 2026

Halia Therapeutics to Participate in Jefferies 2026 Global Healthcare Conference

Halia Therapeutics, known as The Genetic Resilience Company™, is gearing up to make a significant impact at the upcoming Jefferies 2026 Global Healthcare Conference. Scheduled for June 2-4 in New York City, this event serves as a pivotal platform for clinical-stage biopharmaceutical companies aiming to discuss advancements and innovations in healthcare.

The conference will facilitate one-on-one meetings between Halia Therapeutics and institutional investors. These sessions are an excellent opportunity for interested parties to gain insights into Halia's pioneering approaches to inflammation therapies. Investors looking to engage are encouraged to reach out to their representatives at Jefferies to schedule a meeting with the company.

About Halia Therapeutics

Halia Therapeutics is at the forefront of the biopharmaceutical field, focusing on the biology of inflammation. The company has identified significant genetic pathways, specifically the LRRK2 -> RAB10 -> NEK7 -> NLRP3 axis, which contributes to human disease resilience. Leveraging this understanding, Halia is working to translate this biological insight into a series of first-in-class therapeutic programs.

Among their diverse pipeline, key candidates include:

• - HT-6184: Targeting lower-risk myelodysplastic syndromes and other hematologic indications.
• - HT-4253: Developed specifically for Alzheimer’s disease in individuals who are APOE4 carriers.
• - HT-6105: Focusing on reducing residual inflammatory risk through hsCRP reduction.
• - HT-10068: Aimed at tackling metabolic diseases.

Halia's commitment to innovative research shows its potential in revolutionizing treatment approaches for various inflammatory conditions and diseases linked to genetics. As part of its mission, Halia Therapeutics is dedicated to harnessing the power of human genetics to create therapies that not only improve health outcomes but also change the lives of patients.

Conclusion

The Jefferies 2026 Global Healthcare Conference presents a fantastic opportunity for Halia Therapeutics to showcase their pioneering work in the field of inflammation biology. As the company prepares for its participation in this important event, it reaffirms its dedication to advancing first-in-class therapies that could reshape treatment paradigms and ultimately enhance patient lives. For more information about Halia Therapeutics and its innovative pipeline, visit haliatx.com.